LivaNova (NASDAQ:LIVN) Upgraded to Outperform at Robert W. Baird

Robert W. Baird upgraded shares of LivaNova (NASDAQ:LIVN) from a neutral rating to an outperform rating in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage currently has $66.00 target price on the stock, up from their previous target price of $55.00.

Other research analysts also recently issued reports about the company. Stifel Nicolaus boosted their price objective on LivaNova from $70.00 to $72.00 and gave the company a buy rating in a research note on Thursday, July 25th. Needham & Company LLC boosted their price objective on LivaNova from $72.00 to $75.00 and gave the company a buy rating in a research note on Wednesday, July 31st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $70.80.

LivaNova Price Performance

NASDAQ LIVN opened at $51.00 on Tuesday. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.47. The firm has a market capitalization of $2.76 billion, a P/E ratio of -85.00 and a beta of 1.00. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average price of $48.86 and a 200-day moving average price of $53.44.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The firm had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. Equities research analysts anticipate that LivaNova will post 2.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. BNP Paribas Financial Markets boosted its stake in LivaNova by 98.3% in the 4th quarter. BNP Paribas Financial Markets now owns 22,338 shares of the company’s stock worth $1,156,000 after purchasing an additional 11,075 shares during the period. Dimensional Fund Advisors LP boosted its stake in LivaNova by 6.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock worth $64,262,000 after purchasing an additional 74,067 shares during the period. Principal Financial Group Inc. boosted its position in shares of LivaNova by 2.4% during the 4th quarter. Principal Financial Group Inc. now owns 225,385 shares of the company’s stock valued at $11,661,000 after acquiring an additional 5,329 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of LivaNova by 34.6% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 5,521 shares of the company’s stock valued at $286,000 after acquiring an additional 1,418 shares during the last quarter. Finally, Norges Bank bought a new position in shares of LivaNova during the 4th quarter valued at approximately $26,064,000. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.